BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 23, 2007
 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 7/20 cls
Cubist (CBST) JMP Securities Adam Cutler Price target Market outperform 13% $22.11
Lazard Joel Sendek Upgrade Hold (from sell)
Cutler raised his target to $29 from $26 after the company reported 2Q07 GAAP diluted EPS of $0.24, beating his estimate of $0.19. However, he lowered his FY08 EPS estimate to $1.33 from $1.51 to account for an increased diluted share count (see "EPS Watch," A21).
Sendek raised his FY07 and FY08 EPS estimates to $0.74 from $0.39 and to $0.73 from $0.37 to reflect his belief that CBST's Cubicin daptomycin antibiotic faces little competition over the next 6-9 months and that the addition of the drug to the VA formulary should increase sales for the rest of the...

Read the full 794 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >